Cognition Therapeutics, Inc. Common Stock (CGTX)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Cognition Therapeutics, Inc. Common Stock (CGTX) is listed on Nasdaq, where it has traded since October 8, 2021.
- Listed On
- Nasdaq
- Listed Since
- October 8, 2021
- Employees
- 14
- Market Cap
- $91M
About Cognition Therapeutics, Inc. Common Stock
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 62 institutions reported holding CGTX, with 22.6 million shares worth $25.9 million in aggregate. The largest reported holder was Bios Capital Management, with 6.0 million shares worth $6.9 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Bios Capital Management | 6,000,000 | $7M | Unchanged |
| Davenport & | 4,259,511 | $5M | Added 47.24% |
| Vanguard | 3,982,231 | $5M | Added 13.77% |
| BlackRock | 1,261,993 | $1M | Added 30.32% |
| Chescapmanager | 997,029 | $1M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is CGTX?
Cognition Therapeutics, Inc. Common Stock (CGTX) is listed on Nasdaq, where it has traded since October 8, 2021.
Who are the largest institutional holders of CGTX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of CGTX were Bios Capital Management, Davenport & and Vanguard.
How many institutions own CGTX?
62 institutions reported a position in CGTX for the quarter ended June 30, 2026, worth $25.9 million in total.
Did institutions buy or sell CGTX last quarter?
Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for CGTX.
Every reported institutional holder, plus insider and congressional trades in CGTX, on SentiSense.